Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$1.58 USD
+0.03 (1.94%)
Updated Jul 31, 2024 03:59 PM ET
After-Market: $1.58 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BPTH 1.58 +0.03(1.94%)
Will BPTH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BPTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BPTH
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
BPTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BPTH
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Biotech Alert: Searches spiking for these stocks today
Roth MKM Sticks to Their Buy Rating for Bio-Path Holdings (BPTH)
Onsemi Layoffs 2024: What to Know as Onsemi Cuts 1,000 Jobs